tbuckley/cabot-search huggingface dataset:
Correlation between IHC and FISH for HER2/neu assessment in patients with breast cancer
Authors: S. Vigo, A. Mainella, M. Sansano, J. J. Valerga Martin, P. Price, F. Mohamed, M. Antonelli, F. Marmissolle, M. Lamelza, N. Giacomi
Journal: Journal of Clinical Oncology (2008)

20718 Background: HER-2/neu status of the breast cancer (BC) is determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Numerous reports have been published identifying discrepancies between IHC and FISH methods from different manufacturers, as well as tissue processing, reagent variability, antigen retrieval methods, scoring interpretation, tumor heterogeneity, and the semiquantitative nature of the test. The objective was to compare the results of HER-2 assessment by IHC and FISH in patients (pts) with BC being considered for trastuzumab therapy. Methods: For HER2 status review, IHC was used with a policlonal antibody (CB11–1/500), antigenic recovery, Diaminobenzidina (DAKO) and system of detection ENVISION (DAKO). Manual method per protocol of work was used (National Plan Her2). The results were interpreted using score 0 to 3+. FISH was used to assess HER-2 gene amplification. The tumors were tested in two reference centres. All procedures were applied to de-paraffinised tissue sections of BC samples. Results: From July to December 2007, 42 cases of infiltrative BC were studied and correlation with HER-2 overexpression between IHC and FISH was determined. Three plus HER-2 overexpression was found in 9 pts (23%), 2+ in 8 (20%), 1+ in 3 (7,7%) and 0 in 19 (48,7%). In 3 cases this determination was not done. FISH was positive in 14 cases (33,3%) and negative in 28 (66,6%). Only 2/19 (10,5%) IHC score 0 were FISH positive. Four of 8 (50%) IHC 2+ were FISH positive and the other 4 were negative. Only 1 of the 9 IHC score 3+ was FISH negative, so the discordance in this case was 11,1%. Conclusions: We found a significant discordance in 3 cases. Two were IHC score 0 and FISH positive, and 1 was IHC score 3+ and FISH negative. In the 8 cases of IHC score 2+, FISH was used to define positivity: 4/8 (50%) were FISH positive. We suggest to carry out FISH to evaluate the status of HER-2 in BC, especially when is considering the use of trastuzumab therapy. No significant financial relationships to disclose.
Light and Length of Stay in Hospital
Authors: B L Diffey, A Storey
Journal: Journal of the Royal Society of Medicine (1988)

A study was carried out to examine whether the time spent as an inpatient in hospital showed a seasonal dependence which could be attributed to differences in ambient lighting levels between summer and winter. It was found that the season of admission to hospital did not make any appreciable difference to how long patients took to recover before they were discharged.
Does Prostate-Specific Antigen Screening Do More Good Than Harm?
Authors: Andrew J. Vickers
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Ra-223 experience in pretreated patients: EAP setting.
Authors: A. Oliver Sartor, Daniel Celestino Fernandez, Michael J. Morris, Andrei Iagaru, Alan Brown, Fabio Almeida, Christopher Sweeney, Matthew Raymond Smith, Adam Dicker, Yu-Ning Wong, Neal D. Shore, Jeremy Gratt, Oana Petrenciuc, Joseph Germino, Nicholas J. Vogelzang
Journal: Journal of Clinical Oncology (2015)

5063 Background: The early-access program aimed to monitor acute and long-term Ra-223 safety. Herein the number of Ra-223 cycles was examined in relation to prior therapy with abiraterone (abi) and/or enzalutamide (enza). These agents were not approved at the time of the ALSYMPCA trial, the basis for Ra-223 approval. Methods: Symptomatic bone metastatic CRPC patients (pts) and no visceral mets were enrolled in the US if they were ineligible for (or refused) docetaxel (Doc), or had prior Doc. Ra-223 at 50 kBq/kg IV q 4weeks was planned for 6 cycles concomitant with
Simian Virus Tumor Antigen: A Virus-Specific and Preexisting Cell Protein
Authors: Rolf M. Flügel, Hans Fischer
Journal: JNCI Journal of the National Cancer Institute (1975)

The tumor (T) antigen of simian virus 40 (SV40)-transformed SV3T3 cells was immune precipitated with T antiserum obtained from hamsters bearing SV40-induced tumors and with rabbit antiserum to hamster cells. The resulting antigen-double antibody complexes were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Host components of SV40 T antigen with molecular weights of 70,000 and 30,000 were detected.
Familial aggregation of renal disease in a population-based case-control study.
Authors: H H Lei, T V Perneger, M J Klag, P K Whelton, J Coresh
Journal: Journal of the American Society of Nephrology (1998)

Family history of renal disease has been associated with an increased risk of end-stage renal disease (ESRD). It is uncertain whether this risk is mediated by familial aggregation of risk factors for ESRD, such as diabetes and hypertension. The association of ESRD with familial aggregation of renal disease was examined in a large, population-based case-control study conducted in Maryland, Virginia, West Virginia, and Washington, DC. The number of first-degree relatives who were affected with any type of renal disease was compared between 689 newly treated ESRD patients registered in the Medicare ESRD program (92% of all eligible incident cases presenting between January and July of 1991) and 361 control subjects without ESRD who were selected by random-digit dialing (90% response rate). Patients and control subjects were frequency matched by age; patients with ESRD caused by polycystic kidney disease and other known hereditary kidney diseases were excluded. Analysis was conducted using multiple logistic regression. After controlling for the proband's age, gender, race, family size, socioeconomic status, and personal and family histories of diabetes and hypertension, having one first-degree relative with renal disease increased the odds of ESRD by 1.3 (95% confidence interval, 0.7 to 2.6) and having two or more affected first-degree relatives increased the odds of ESRD by 10.4 (95% confidence interval, 2.7 to 40.2). These data support familial aggregation of renal disease in excess of that predicted by clustering of diabetes and hypertension within families, suggesting that either genetic susceptibility or environmental exposures shared within families increase the risk of developing ESRD. This risk is also much higher when two or more first-degree relatives have renal disease. Unraveling the molecular basis of this increase in risk may provide new avenues for treatment and prevention of ESRD.
PTH-057 Dendritic cell phenotype in crohn’s disease may correlate with disease severity and explain the high prevalence of cutaneous manifestations
Authors: PA Hendy, D Bernardo, HO Al-Hassi, NS Ding, D Reddi, YH Siaw, S Knight, AL Hart
Journal: Gut (2015)

<h3>Introduction</h3> Dendritic cells (DC) are potent antigen presenting cells that bridge the innate and adaptive immune systems. Altered function and phenotype of human blood DC has been described in inflammatory bowel diseases including Crohn’s disease (CD), with peripheral blood DC displaying more inflammatory and fewer tolerogenic characteristics in CD than in healthy controls (HC). However, the correlation between CD severity and the expression of DC phenotypic molecules is still unknown. Here we use flow cytometry to assess this correlation. <h3>Method</h3> Blood was taken from patients with CD and HC and a Ficoll density gradient was used to separate and isolate the peripheral blood mononuclear cells. Multicolour flow cytometry was performed to assess DC which were identified as being both HLA-DR positive and negative for the usual DC lineage markers (CD3, 14, 16, 19, 32). DC were further divided as myeloid (mDC, CD11c+CD123-) and plasmacytoid (pDC, CD11c-CD123<sup>+</sup>). Expression of co-stimulatory and homing molecules on DC was assessed by flow cytometry. Disease severity was assessed by both the Harvey-Bradshaw index and by faecal calprotectin. <h3>Results</h3> 6 patients with CD and 2 HC were recruited. Expression of the co-stimulatory molecules CD40 and CD80 on mDC correlated with disease severity as assessed by the Harvey-Bradshaw index (p = 0.078 and 0.048 respectively) and the same was found on pDC (p = 0.008 and 0.0311 respectively). There was a non-significant trend toward correlation for the co-stimulatory molecule CD86 (p = 0.065). Expression of the homing marker CLA (skin homing) was raised in CD (p = 0.043) and correlated with disease severity (as assessed by faecal calprotectin levels) in CD (p = 0.0078). <h3>Conclusion</h3> A correlation between expression of DC co-stimulatory molecules and CD severity was found. This is a novel finding and suggests a potential role for these molecules as biomarkers. We also show that peripheral blood DC expression of the skin homing molecule CLA is higher in CD than in healthy controls and increases in more active disease. This may help explain both the high rates of cutaneous manifestations (including erythema nodosum) in CD, and the fact that these cutaneous presentations most often occur in the context of active disease. <h3>Disclosure of interest</h3> None Declared.
Abstract 4692: BGB-283, a novel RAF kinase and EGFR dual inhibitor, displays potent antitumor activity in B-RAF mutated colorectal cancers
Authors: Zhiyu Tang, Xi Yuan, Rong Du, Shing-Hu Cheung, Guoliang Zhang, Jing Wei, Yuan Zhao, Yingcai Feng, Yi Zhang, Yunguang Du, Xiaoxia Hu, Wenfeng Gong, Yong Liu, Yajuan Gao, Rui Hao, Jiafu Ji, Lianhai Zhang, Shuangxi Li, David Sutton, Min Wei, Changyou Zhou, Lai Wang, Lusong Luo
Journal: Cancer Research (2015)

Abstract Oncogenic B-RAF, which drives cell transformation and proliferation, has been detected in approximately 70% of human malignant melanomas and 5-15% of colorectal cancers (CRC). B-RAFV600E mutation, which gives rise to constitutive MAPK signaling, accounts for at least 90% of oncogenic B-RAF mutations. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating B-RAFV600E metastatic melanoma, their clinical efficacy in B-RAFV600E CRC is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon B-RAF inhibition contributed to the intrinsic resistance of CRC to the first generation B-RAF inhibitors. This report represents the first characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigations. BGB-283 is a potent and selective pan-RAF and EGFR inhibitor with IC50 ranging from 5 to 47 nM on RAF and EGFR kinases. In vitro, BGB-283 potently inhibits B-RAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harbouring B-RAFV600E and EGFR mutation/amplification. In B-RAFV600E CRC cell lines, BGB-283 effectively inhibits the reactivation of EGFR and achieved sustained inhibition of MAPK pathway. In vivo, BGB-283 is highly efficacious in inhibiting tumor growth accompanied by partial and complete tumor regressions in both BRAFV600E mutant cell derived CRC xenograft models, including HT29, Colo205, WiDr, as well as two primary human CRC xenograft models. In particular, BGB-283 shows compelling efficacy and potent inhibition of EGFR/MAPK signaling in WiDr xenograft model where EGFR reactivation occurs upon B-RAF inhibition. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating CRC harboring B-RAFV600E mutation. Citation Format: Zhiyu Tang, Xi Yuan, Rong Du, Shing-Hu Cheung, Guoliang Zhang, Jing Wei, Yuan Zhao, Yingcai Feng, Yi Zhang, Yunguang Du, Xiaoxia Hu, Wenfeng Gong, Yong Liu, Yajuan Gao, Rui Hao, Jiafu Ji, Lianhai Zhang, Shuangxi Li, David Sutton, Min Wei, Changyou Zhou, Lai Wang, Lusong Luo. BGB-283, a novel RAF kinase and EGFR dual inhibitor, displays potent antitumor activity in B-RAF mutated colorectal cancers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4692. doi:10.1158/1538-7445.AM2015-4692
Expression of Axl Receptor and Its Ligand Gas6 in Colorectal Cancer (Crc)
Authors: C. Cardone, G. Liguori, T. Troiani, A. Nappi, N. Amoroso, V.R. Iaffaioli, C. Romano, G. Botti, D. Vitagliano, G. Martini, S. Napolitano, F. Morgillo, V. Sforza, E. Giunta, M. Di Maio, F. De Vita, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2014)
Safety and Efficacy of Regorafenib in National Cancer Center Hospital East (Ncche)
Authors: Shota Fukuoka, Kohei Shitara, Mai Itagaki, Masaaki Noguchi, Tomoji Kato, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Nozomu Fuse, Takayuki Yoshino
Journal: Annals of Oncology (2014)
Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy
Authors: D B Carr, D V Sheehan, O S Surman, J H Coleman, D J Greenblatt, G R Heninger, K J Jones, P H Levine, W D Watkins
Journal: American Journal of Psychiatry (1986)

Lactate infusions are anxiogenic in patients with panic disorder or agoraphobia with panic attacks, but few neuroendocrine profiles of this effect have appeared. The authors measured the number and intensity of panic symptoms and blood hormone levels during double-blind lactate infusions in 25 patients and 10 normal subjects and during placebo infusions in another five patients. Each patient was rechallenged with an identical infusate after chronic double-blind outpatient treatment with alprazolam or placebo. The results confirm the effectiveness of lactate infusions in evoking anxiety, extend previous hormone profiles of this maneuver, and indicate that chronic alprazolam treatment minimizes the neuroendocrine response to lactate challenges in patients with panic disorder or agoraphobia with panic attacks.
Visible and Invisible Trends in Black Men's Health: Pitfalls and Promises for Addressing Racial, Ethnic, and Gender Inequities in Health
Authors: Keon L. Gilbert, Rashawn Ray, Arjumand Siddiqi, Shivan Shetty, Elizabeth A. Baker, Keith Elder, Derek M. Griffith
Journal: Annual Review of Public Health (2015)

Over the past two decades, there has been growing interest in improving black men's health and the health disparities affecting them. Yet, the health of black men consistently ranks lowest across nearly all groups in the United States. Evidence on the health and social causes of morbidity and mortality among black men has been narrowly concentrated on public health problems (e.g., violence, prostate cancer, and HIV/AIDS) and determinants of health (e.g., education and male gender socialization). This limited focus omits age-specific leading causes of death and other social determinants of health, such as discrimination, segregation, access to health care, employment, and income. This review discusses the leading causes of death for black men and the associated risk factors, as well as identifies gaps in the literature and presents a racialized and gendered framework to guide efforts to address the persistent inequities in health affecting black men.
New drug delivery approach for the treatment of prostate cancer (preclinical results and phase I study results)
Authors: M. Dhawan, D. Price, D. Trump, P. Kanter, N. Shore, D. Needham, M. Dewhirst
Journal: Journal of Clinical Oncology (2004)

4661 Introduction: Treatment for localized prostate cancer includes observation, radiation and surgical therapy with or without androgen deprivation.. One potential relevant form of therapy is thermal therapy plus thermally sensitive liposomal encapsulated cytotoxic agents administered systemically, concentrated in the prostate, where the focused heat triggers drug release from the liposome. Methods: Extensive animal studies were performed in rodents and dogs to support the ongoing clinical study for the treatment of Prostate cancer . A study in dogs tested whether the BPH800 System, a transurethral microwave catheter heating system, would heat the prostate to temperatures high enough to activate the heat-sensitive liposomes. Detailed large and small animal toxicology studies were also performed. Preclinical Results: The drug is active against a range of xenografts, including PC3, a prostate tumor line, when the tumor region is heated to temperatures that lead to rapid drug release from the liposomes. Enhanced growth delay was observed, when compared with heat alone and drug alone. Dog studies demonstrated that the BPH800 System is capable of providing safe and reliable thermal therapy in that it consistently applied the heat needed to maintain the prostate at the liposomal drug-release temperature of 41°C–42°C for 60 minutes. The toxicology studies in large dogs established that the DLT was slightly lower than that of free drug. These data were used to design the starting dose for Phase I trials. Clinical Results: The preclinical study results led to FDA clearance to conduct the first Phase I dose escalation trial to determine the MTD, PK, & safety of Thermadox™ when activated with thermal therapy for the treatment of prostate cancer. The study is currently in process and will be completed in early 2004. The poster will describe the framework of the Phase I study and its results. Conclusions: Assessment of the safety and efficacy of the treatment of prostate cancer is in progress; enrollment is continuing for the first Phase I study. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celsion Corp. Celsion Corp. Celsion Corporation
Abstract 12757: Fluvastatin-induced Improvement of Redox Imbalance Ameliorates Diabetic Cardiomyopathy in Association With Improving Coronary Microvasculature
Authors: takuya shida
Journal: Circulation (2012)

Background: Diabetic cardiomyopathy is associated with increased oxidative stress as well as vascular endothelial dysfunction leading to myocardial microangiopathy. We tested the hypothesis that th...
A5.01 The relationship between total knee replacement and 3D MRI knee bone shape: Data from the osteoarthritis initiative
Authors: AJ Barr, B Dube, EMA Hensor, SR Kingsbury, G Peat, MA Bowes, LD Sharples, PG Conaghan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Imaging biomarkers of osteoarthritis (OA) structural progression are more accurate when derived from MRI than conventional radiography. Accurate 3D quantification of MRIs is achieved using active appearance modelling (AAM). Subchondral bone shape changes are integral to OA structural progression and are predictive of incident radiographic knee OA. We aimed to determine the relationship between scalar 3D bone shape and total knee replacement (TKR). <h3>Materials and methods</h3> This case-control analysis, nested within the osteoarthritis initiative (OAI) cohort, matched 1:1 control knees that "survived" 6 years of follow up with case knees undergoing TKR, using stratification (propensity) score matching based upon baseline age, BMI, gender, knee side, ipsilateral knee pain severity and recruiting centre. AAM of the patella, tibia and femur were used to identify vectors that best classified knees as having OA vs. no OA, scaled such that -1 and +1 represented the mean non-OA and mean OA shapes, respectively. Within matched case-control pairs, the vector values were compared using paired t-tests and using conditional logistic regression, the odds of TKR per unit of 3D bone shape were obtained. <h3>Results</h3> Case-control pairs (n = 311) of knees were well matched based upon propensity scores. Amongst the 311 well matched pairs, mean baseline 3D bone shape vector of TKR cases was more positive (more advanced OA) relative to controls, for the femur [mean 0.98 vs. -0.16; difference (95% CI) 1.14 (0.92,&nbsp;1.37)], tibia [mean 0.86 vs. -0.05; difference (95% CI) 0.90 (0.69,&nbsp;1.12)] and patella [mean 0.95 vs. -0.07; difference (95% CI) 1.02 (0.74,&nbsp;1.31)]. Unadjusted conditional odds ratios (95% CI) for the femur, tibia and patella revealed increased odds of TKR with increasingly positive 3D bone shape vector values (increasing OA structural severity). After Kellgren Lawrence (KL) grade adjustment in a multivariable analysis, femoral 3D shape vector was independently associated with TKR [OR 1.21 (1.01, 1.45)] with an improvement in model fit (AIC) compared with KL grade. <h3>Conclusions</h3> 3D bone shape is associated with TKR. Femur shape has the greatest association with TKR. This provides evidence of predictive validity of 3D bone shape and its potential utility in trials of prospective disease modifying OA drugs.